Project Grant HT94252310397

The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to validate a novel preclinical mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test prevention agents. The $602,315 award to the University of Colorado-Denver will: Define the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignant lesions. Validate an ex vivo precision cut lung slice...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...

This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...

This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...